Company intelligence / Profile preview

InterCure Ltd.

Ownership: Public · INCR
Employees: ~270
Development stage: Other

Overview

InterCure Ltd. researches, cultivates, produces, and distributes pharmaceutical-grade cannabis and related products for medical use in Israel and internationally. The company has transitioned from traditional biotech/pharma to focus on the medical cannabis sector since its founding in 1994.

No clinical trial results are specifically mentioned; the company operates at a commercial stage with established product offerings.

Therapeutic areas: Neurology
Modalities: Cannabis-based products (dried cannabis inflorescences, cannabis extract mixed with oil)
Industry: Biotech

Drug pipeline

1 asset

Canndoc T1/C20

Unknown

Financials

Market cap: $39M
Total revenue: $84.8M
Enterprise value: $81.8M

Beyond the preview

Go deeper on InterCure Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterCure Ltd..